The U.S. Senate unanimously passed the Accelerating Access to Critical Therapies (ACT) for ALS Act, legislation introduced by U.S. Senators Chris Coons (D-Del.) and Lisa Murkowski (R-Alaska) and U.S. Representatives Mike Quigley (D-Ill.) and Jeff Fortenberry (R-Neb.). The bipartisan, bicameral bill passed the U.S. House of Representatives last week. The ACT for ALS Act would fund essential research into fast-progressing rare neurodegenerative and terminal diseases, like amyotrophic lateral sclerosis (ALS), and early access to promising investigational therapies for patients suffering from them and would authorize $100 million annually to implement these priorities. ALS affects 1 in 300 people, often leaving patients with no more than three years to live following their diagnosis, and disproportionately impacts U.S. military service members. ACT for ALS authorizes new grants to support expanded access and research programs. This expansion will bring investigational treatments for rapidly progressing diseases beyond their ongoing clinical trials to patients with diseases for which effective therapies don’t already exist and allow for additional research into the effectiveness of those interventions. It also creates a new Food and Drug Administration (FDA) Rare Neurodegenerative Disease Grant Program to support other research and development on ALS and other life-threatening or severely debilitating neurodegenerative diseases. More details here: https://www.coons.senate.gov/news/press-releases/act-for-als-act-unanimously-passes-senate-heads-to-president-biden-for-his-signature